Blood pressure reduction due to hemoglobin glycosylation in type 2 diabetic patients

Pedro Cabrales
Miguel A Salazar Vázquez
Beatriz Y Salazar Vázquez
Martha Rodríguez-Morán
Marcos Intaglietta
Fernando Guerrero-Romero

La Jolla Bioengineering Institute, La Jolla, California, USA; Hospital Regional No. 1, of the Mexican Social Security Institute, Victoria de Durango, Dgo. Mexico; Faculty of Medicine and Dept. of Physical Chemistry, Universidad Juárez del Estado de Durango, Victoria de Durango, Dgo. Mexico; Department of Bioengineering, University of California, San Diego, La Jolla, California, USA; Biomedical Research Unit, of the Mexican Social Security Institute, Victoria de Durango, Dgo. Mexico

Objective: To test the hypothesis that glycosylation of hemoglobin constitutes a risk factor for hypertension.

Methods: A total of 129 relative uniform diabetic subjects (86 women and 42 men) were enrolled in a cross-sectional study. Exclusion criteria included alcohol consumption, smoking, ischemic heart disease, stroke, neoplasia, renal, hepatic, and chronic inflammatory disease. Systolic and diastolic pressures were recorded in subsequent days and mean arterial blood pressure (MAP) was determined. Hemoglobin glycosylation was measured by determining the percentage glycosylated hemoglobin (HbA1c) by means of the automated microparticle enzyme immunoassay test.

Results: MAP was found to be independent of the concentration of HbA1c; however, correcting MAP for the variability in hematocrit, to evidence the level of vasoconstriction (or vasodilation) showed that MAP is negatively correlated with the concentration of HbA1c (p for trend <0.05), when patients treated for hypertension are excluded from the analysis. Patients treated for hypertension showed the opposite trend with increasing MAP as HbA1c increased (p for the difference in trends <0.05).

Conclusions: Glycosylation per se appears to lead to blood pressure reduction in type 2 diabetic patients untreated for hypertension. Treatment for hypertension may be associated with a level of endothelial dysfunction that interferes with the antihypertensive effect of HbA1c.

Keywords: diabetes, hemoglobin glycosylation, hypertension, hematocrit, nitric oxide

Introduction

Glycosylated hemoglobin (HbA1c, % HbA1c relative to total hemoglobin, Hb), indicating average plasma glucose over 3 months is highly correlated with most of the excess mortality risk of diabetes, which rises continuously beyond a 5% glycosylation index (~0.7 g/dl concentration) (van Hoeven and Factor 1990; Grossman and Messerli 1996; Khaw et al 2001). This relationship is attributed in part to an impairment of the rheological properties of blood, leading to increase red blood cell (RBC) stiffness, and alterations of plasma viscosity due to the interaction of uncontrolled plasma glucose levels with plasma proteins. There is also evidence that glycosylation of hemoglobin impairs nitric oxide (NO) related relaxation of human mesenteric vessels (Vallejo et al 2000) and it has been shown that Hb glycosylation alters NO binding to Hb thiols, lowering NO bioavailability and impairing vasodilation in rabbit aortic rings (James et al 2004).

Microvascular NO bioavailability is a complex balance of NO production by the endothelium and NO scavenging and transport by Hb in RBCs. Blood flow and viscosity determine shear stress on the glycocalix/endothelium modulating the rate of production of NO by the endothelium via biochemical mechano transduction (Frangos et al 1996). This mechanism provides a form of autoregulation by which increases in peripheral vascular resistance due to anatomical or rheological changes increase shear stress and the release of endothelial dependant vasodilators, tending to normalize
vascular resistance by lowering vessel tone. In normal healthy individuals additional autoregulatory mechanisms strive to optimize blood pressure and oxygen delivery, compensating for changes in blood viscosity due to the natural variability of this parameter due to fluid intake, alimentation, environmental adaptation, and some disease conditions. This effect was demonstrated by Martini and colleagues (2005) who increased hematocrit (Hct) and blood viscosity within the normal range of variability in healthy experimental animals, reducing peripheral vascular resistance and blood pressure and increasing cardiac index.

The %HbA1c increase in conditions of poor diabetic control is associated with increasing blood viscosity (Leiper et al 1984). Glycosylation of hemoglobin (Hb) may also change membrane lipid-protein interactions in RBCs changing their internal viscosity, altering viscoelastic properties of erythrocyte membranes and impairing RBC deformability (Watala et al 1992). RBC deformability in nephrotic patients is reduced, an effect associated with the abnormal carbohydrate metabolism level and the increased HbA1c characteristic of this syndrome (Cecchin et al 1987).

Although glycosylation of Hb is a marker for significant cardiovascular risk, it is not clear whether it constitutes a risk. However, cumulative impairment of NO transport by HbA1c could constitute a significant risk factor in view of its direct implication in promoting hypertension, ischemia and enhanced production of oxygen free radicals. Notably these concepts arise primarily from in vitro tests. In the present study we investigated the relationship between HbA1c index and concentration, blood glucose, mean arterial pressure (MAP), and Hct in a relatively uniform diabetic population of Victoria de Durango, a city in northern Mexico, to test the hypothesis that glycosylation of Hb constitutes a risk factor for hypertension.

**Material and methods**

A total of 129 subjects (86 women and 42 men) with previous diagnosis of type 2 diabetes were enrolled in a cross-sectional study.

Protocol approval was obtained from the Mexican Social Security Institute (MSSI) Research Committee and informed consent was provided by each individual.

Exclusion criteria included alcohol consumption ≥30 g per week (Reynolds et al 2003), smoking, ischemic heart disease, stroke, neoplasia, renal, hepatic, and chronic inflammatory disease.

Blood pressure was measured on subsequent days, according with the VI Joint National Committee recommendation (JNC 1997). Systolic (SBP) and diastolic (DBP) blood pressures were recorded and MAP was determined using the relationship:

\[
\text{MAP} = \text{P}_{\text{diastolic}} + \frac{1}{3}(\text{P}_{\text{systolic}} - \text{P}_{\text{diastolic}})
\]

Hemoglobin glycosylation was measured by determining the %HbA1c by means of the automated microparticle enzyme immunoassay (IMx, Abbot Laboratories, USA) test.

Mean arterial blood pressure was normalized vs. Hct using the relationship:

\[
\text{MAP}_n = \frac{\text{MAP}_i \cdot \text{Hct}_{\text{ave}}}{\text{Hct}_i}
\]

where \(\text{MAP}_n\) is the normalized blood pressure of an individual, \(\text{Hct}_{\text{ave}}\) is the average Hct in the population sample, and \(\text{Hct}_i\) is the Hct of the individual.

The %HbA1c was converted from a relative quantity to an absolute concentration in blood by multiplying this parameter by Hct, using the average Hct for this population of 43.0% and assuming that blood hemoglobin content is 14.5 g/dl. The following equation was used to normalize each individual:

\[
\text{CHbA1c}_i = \%\text{HbA1c}_i \times \frac{14.5 \times \text{Hct}_i}{\text{Hct}_{\text{ave}}}
\]

where \(\text{CHbA1c}_i\) is the concentration of HbA1c in blood in g/dl.

Blood samples (3 ml) were drawn from the antecubital vein, 8 to 10 h after fasting, and collected in tubes with EDTA for Hct measurements. Hct was measured using a microhematocrit centrifuge (13,000 g for 3 min at 20 °C, Sol-Bat Centrifuge M-600, Readacrit L-10, Mexico). In addition, 3 ml blood samples were drawn in tubes without anticoagulants for glucose measurements.

**Statistical analysis**

Pearson’s analysis was performed to examine the correlation between %HbA1c, glucose level, blood pressure, and Hct. For the purpose of statistical analysis, all the skewed numerical data were transformed by Log \(n\), to obtain a symmetrical distribution. Data were analyzed using the statistical package SPSS 12.0 (SPSS Inc., Chicago, IL, USA). A 95% confidence interval (95% CI) was considered, and \(p < 0.05\) defined the level of statistical significance.

**Results**

Previously diagnosed diabetic patients that had undergone hypoglycemic treatment for a minimum period of 8 years were enrolled from the First Medical Care Level Offices of
the MSSI in Victoria de Durango, Mexico. A total of 187 type 2 diabetic patients with average glycemia of 213 ± 99 mg/dl were screened for hypertension and included in the study if SBP was ≤ 130 mmHg and/or DBP ≤ 85 mmHg. Fifty-eight patients (32%) were not included because they did not fulfill the inclusion-exclusion criteria; finally, a total of 129 diabetic patients were enrolled.

Amongst the included persons, 31 (24.0%) were hypertensive and received pharmacological treatment with captopril (n = 22), nifedipine (n = 4), metoprolol (n = 3), and combined therapy (n = 2). None of the patients were treated with diuretics, and none of the treatment modalities is known to affect the concentration of HbA1c. Patients treated for hypertension were analyzed independently from the non treated diabetic patients; however the untreated population was not statistically different from the treated population with the exception of blood pressure (p < 0.001) as shown in Table 1.

The correlation between MAP and HbA1c % for the whole population sample of 129 patients including patients treated and untreated for hypertension was negative but not statistically significant (p = 0.24).

The correlation between MAP and HbA1c when patients were separated into treated vs. non treated for hypertension was negative for untreated patients and positive for treated patients, however neither correlation was significant, although the difference in trends approached significance (p = 0.06).

Normalizing MAP relative to Hct, yielded a negative nonsignificant (p = 0.19) correlation between MAP of patients not treated for hypertension and %HbA1c. Patients treated for hypertension showed a significant positive trend (p = 0.02), and the difference in trends was highly significant (p = 0.007), a result shown in Figure 1.

The correlation between normalized MAP and HbA1c converted from % of blood hemoglobin to actual concentration (g/dl) is shown in Figure 2 for diabetics untreated and treated for hypertension. The trend had a statistically significant (p = 0.04) negative correlation for untreated patients and a positive nonsignificant (p = 0.22) correlation for treated patients. The difference in trends however was statistically significant (p = 0.04).

The decrease of blood pressure as a function of increased %HbA1c suggests that a factor affecting the relationship between MAP and Hct may be microalbuminuria, which is related to increased permeability caused by HbA1c, and which could affect Hct. However, although there was a slightly positive functional dependence between these parameters, it was not statistically significant (r² = 0.002 and p = 0.66).

Discussion
The principal finding of this study is that MAP in a comparatively uniform population of diabetic of fairly similar racial

Table 1 Population characteristics of diabetic type 2 patients treated for hypertension vs untreated

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Untreated</th>
<th>Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>98</td>
<td>31</td>
</tr>
<tr>
<td>Female/male</td>
<td>67/31</td>
<td>20/11</td>
</tr>
<tr>
<td>Age, years</td>
<td>52.6 ± 4.1</td>
<td>51.5 ± 4.2</td>
</tr>
<tr>
<td>Glucose</td>
<td>220 ± 78</td>
<td>192 ± 94</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>252 ± 58</td>
<td>240 ± 52</td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>42.8 ± 2.4</td>
<td>43.7 ± 4.5</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>9.3 ± 2.6</td>
<td>9.2 ± 2.3</td>
</tr>
<tr>
<td>Mean arterial blood pressure, mmHg</td>
<td>89.7 ± 13.6</td>
<td>101.8 ± 12.5</td>
</tr>
</tbody>
</table>

Notes: Mean ± standard deviation. All parameters not statistically different (p > 0.05), with the exception of mean arterial blood pressure (p < 0.001).

Abbreviation: HbA1c, glycosylated hemoglobin.
and ambient characteristic is unrelated to the glycosylation index of Hb when this ranges from 0.5 to 2.6 g/dl plasma. Separating from this population individuals treated for hypertension shows that there is a statistically significant negative correlation between MAP normalized relative to Hct versus the concentration of HbA1c.

Normalizing MAP relative to Hct renders the measured blood pressure independent of blood viscosity, and reveals whether MAP is a function of vascular regulation or the change in flow properties of blood. Thus normalizing MAP relative to Hct is a means for identifying effects on blood pressure due to vasoactivity vs. those due to the viscosity of blood determined by Hct, which presents a natural variability in the population. When the effect of blood viscosity is approximately neutralized by the normalization procedure blood pressure becomes directly related to the level of tone of the vasculature, i.e., whether it is constricted or vasodilated, if we assume that anomalies of cardiac function, circulating blood volume, baroreceptor reflexes, etc., randomly affect blood pressure and are unrelated to Hb glycosylation. In the present case, it appears that individuals not treated for hypertension may be progressively vasodilated in proportion of the increase of total and/or relative HbA1c concentration increases. In this study we normalized blood pressure versus Hct since a previous study by Salazar-Vázquez and colleagues (2006), in the same population of diabetic patients, shows a “U” shaped distribution of MAP versus Hct. Regarding the statistical differences found between the different treatments of the data, it appears that the assessment of cardiovascular risk may be more evident when using hematocrit corrected MAP data versus %HBA1c. However the fundamental difference between the two populations is expressed regardless of the difference in treatment of the data.

Since 8%–10% HbA1c is considered to be a threshold beyond which the effects of hemoglobin glycosylation become significant we determined MAP for patients not treated for hypertension below and above 9% HbA1c, and found that below the threshold MAP was 86.2 ± 3.9 mmHg and 93.1 ± 12.5 mmHg above the threshold, the difference being statistically significant (p < 0.001), confirming the trend found when the data was analyzed as a whole. These results show that Hb glycosylation is not associated with the increase of the anatomical component of peripheral vascular resistance in individuals not treated for hypertension. Therefore the impairment of NO bioavailability leading to vasoconstriction postulated by in vitro studies in aortic rings does not appear to obtain in vivo (James et al 2004). It is furthermore apparent that solely on the basis of the effect that vasodilation and vasoconstriction has on blood pressure, there is no evidence that “…glycosylation impairs the NO vasodilator function of RBCs within the physiological range of tissue oxygenation” (James et al 2004). Remarkably James and colleagues (2004) found significant inhibition of hypoxic relaxation effects when HbA1c was 10.7% of human red blood cell was used in the perfusion of rabbit aortic rings. Conversely, our study failed to demonstrate an effect on blood pressure when individuals had HbA1c that was as much as 26% of the total RBCs. Thus the rabbit aortic rings study exposed to human glycosylated RBCs show vasoactivity that may be uncorrelated to that expected in a human cross-sectional study.

Translation and relevance of isolated tissue studies to in vivo conditions in humans is always a difficult endeavor, because the isolated tissue is not exposed to the full spectrum of phenomena operational in vivo. While it is undeniable that aortic rings exhibit a greater constriction tendency when
exposed to glycosylated RBCs, our study shows that this phenomenon does not correspond to the increase of blood vessel tone dependant peripheral vascular resistance in the population at risk, and that the opposite may obtain.

There are several mechanisms that may in part explain our findings. A mechanism by which glycosylation of Hb is proposed to be vasoactive is via the formation of reactive oxygen species (ROS) (Angulo et al 1996) however this process is significantly mitigated inside RBCs. Glycosylation of Hb also lowers oxygen carrying capacity, promoting hypoxia and its related systemic vascular vasodilatory adaptations and responses (Paffett and Walker 2007).

Glycosylation of Hb as well as increased glucose levels tends to affect primarily RBC properties, lowering the RBC flexibility and increasing aggregability, the latter potentially increasing blood viscosity (Buhler et al 2001). Blood viscosity is one of the determinants of shear stress and peripheral vascular resistance via mechano-transduction. It should be noted that increased blood viscosity is not necessarily pathological, since it can be instrumental in increasing shear stress, enhancing the production of endothelial NO, compensating for the effect of viscosity on peripheral vascular resistance via vasodilatation. In this context decreased RBC flexibility has a moderate effect in increasing blood viscosity, which may in part explain the tendency for a negative correlation between glycosylation index and blood pressure.

The characteristic of the population studied were relatively uniform, in terms of age, duration of diabetes, cholesterol, and hematocrit, but differed significantly in MAP which was the cause for treatment of this segment of the population. The finding that the subgroup of patients treated for hypertension presents a statistically significant positive correlation with the increase of HbA1c suggests that in this population that requires a direct intervention for the control of MAP, endothelial dysfunction was significant. Consequently the presence of glycosylated Hb did not provide any compensatory effects at the level of the endothelium. In this context it appears that in diabetic patients that require treatment for hypertension hemoglobin glycosylation aggravates the consequences of endothelial dysfunction.

In conclusion, the existence of a negative, statistically significant correlation between MAP and the concentration of glycosylated Hb suggests that this parameter is not an indicator of hypertension. Increased HbA1c concentration should increase blood viscosity, peripheral vascular resistance, and blood pressure. Furthermore glycosylation of hemoglobin per se should impair the NO vasodilator function of RBC. However the lack or opposite consequence of these effects was found in a population of type 2 diabetic patients not treated for hypertension. The effects of hemoglobin glycosylation are mostly deduced from in vitro and tissue studies that do not correspond to physiological conditions, highlighting the difficulty of translating experimental findings to conditions in the human population. In vivo increased blood viscosity also leads to increased shear stress and therefore NO production by the endothelium, therefore if endothelial impairment is not present, then the potential, albeit small, increase in blood viscosity due to Hb glycosylation may be beneficial, although other rheological effects such as decreased RBC flexibility may adversely affect capillary perfusion. Finally diabetic patients requiring treatment for hypertension appear unable to compensate for the increased levels of HbA1c, confirming the presence of endothelial dysfunction, and possibly the impairment of hypoxic dilatation regulation.

**Acknowledgments**

This research was conducted with the financial support from the USPHS grants R01-HL62354 and R01-HL62318 to MI. Marcos Intaglia is a member of the Board of Directors of the La Jolla Bioengineering Institute. In addition, this work was supported by grants from the Research Fund of Durango’s State-National Science and Technology Council of Mexico (FOMIX Dgo-2002-C01-3760), the Research Promotion Fund of the Mexican Social Security Institute (FP 2002/366), and the Mexican Social Security Institute Foundation, Civil Association.

**References**


